We are live on ! Find out more
MNTA

Momenta Pharmaceuticals
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

154 hedge funds and large institutions have $1.27B invested in Momenta Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 47

31% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.15M

28% more capital inflows, than outflows

Capital inflows: $67M | Capital outflows: $52.3M

1.17% more ownership

Funds ownership: 98.26% → 99.43% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less funds holding

Funds holding: 155 → 154 (-1)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

Holders
154
Holders Change
-1
Holders Change %
-0.65%
% of All Funds
3.36%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
64
Reduced
47
Closed
16
Calls
$1.51​M
Puts
$1.15​M
Net Calls
+$358​K
Net Calls Change
+$380​K

MNTA Hedge Fund Activity: Q3 2019 in Review

154 of the 4,577 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals (MNTA) for Q3 2019, worth a combined $1.27B — up 5.5% from $1.21B a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of MNTA and 15 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 64 added.

The largest buyer was Point72 Asset Management, adding an estimated $28.7M. The largest seller was Wellington Management Group, cutting an estimated $6.28M.

  • 154 institutional investors held Momenta Pharmaceuticals (MNTA) as of Q3 2019, down from 155 in Q2 2019.
  • Funds reported $1.27B of Momenta Pharmaceuticals stock for Q3 2019, up 5.5% quarter-over-quarter.
  • 15 funds opened new Momenta Pharmaceuticals positions in Q3 2019 and 16 closed out, a net change of -1 holder.
  • The largest Momenta Pharmaceuticals buyer in Q3 2019 was Point72 Asset Management, an estimated $28.7M added.
  • The largest Momenta Pharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $6.28M sold.

Based on aggregated 13F filings for Q3 2019.